Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization
Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Scaruffi, Paola [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2004 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Adis Data Information BV 2004 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Molecular diagnosis & therapy - [S.l.] : Springer International, 2006, 8(2004), 2 vom: Juni, Seite 93-100 |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2004 ; number:2 ; month:06 ; pages:93-100 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03260051 |
|---|
| Katalog-ID: |
SPR035370548 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR035370548 | ||
| 003 | DE-627 | ||
| 005 | 20230519114446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2004 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03260051 |2 doi | |
| 035 | |a (DE-627)SPR035370548 | ||
| 035 | |a (SPR)BF03260051-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scaruffi, Paola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Adis Data Information BV 2004 | ||
| 520 | |a Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. | ||
| 650 | 4 | |a Neuroblastoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Comparative Genomic Hybridization |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a MYCN Amplification |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neuroblastoma Patient |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a MYCN Gene |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Parodi, Stefano |4 aut | |
| 700 | 1 | |a Mazzocco, Katia |4 aut | |
| 700 | 1 | |a Defferrari, Raffaella |4 aut | |
| 700 | 1 | |a Fontana, Vincenzo |4 aut | |
| 700 | 1 | |a Bonassi, Stefano |4 aut | |
| 700 | 1 | |a Tonini, Gian Paolo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular diagnosis & therapy |d [S.l.] : Springer International, 2006 |g 8(2004), 2 vom: Juni, Seite 93-100 |w (DE-627)51122799X |w (DE-600)2232973-0 |x 1179-2000 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2004 |g number:2 |g month:06 |g pages:93-100 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03260051 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_150 | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2004 |e 2 |c 06 |h 93-100 | ||
| author_variant |
p s ps s p sp k m km r d rd v f vf s b sb g p t gp gpt |
|---|---|
| matchkey_str |
article:11792000:2004----::eetoomcapiiainncrmsm13lsinuolsoaydairary |
| hierarchy_sort_str |
2004 |
| publishDate |
2004 |
| allfields |
10.1007/BF03260051 doi (DE-627)SPR035370548 (SPR)BF03260051-e DE-627 ger DE-627 rakwb eng Scaruffi, Paola verfasserin aut Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2004 Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. Neuroblastoma (dpeaa)DE-He213 Comparative Genomic Hybridization (dpeaa)DE-He213 MYCN Amplification (dpeaa)DE-He213 Neuroblastoma Patient (dpeaa)DE-He213 MYCN Gene (dpeaa)DE-He213 Parodi, Stefano aut Mazzocco, Katia aut Defferrari, Raffaella aut Fontana, Vincenzo aut Bonassi, Stefano aut Tonini, Gian Paolo aut Enthalten in Molecular diagnosis & therapy [S.l.] : Springer International, 2006 8(2004), 2 vom: Juni, Seite 93-100 (DE-627)51122799X (DE-600)2232973-0 1179-2000 nnns volume:8 year:2004 number:2 month:06 pages:93-100 https://dx.doi.org/10.1007/BF03260051 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 AR 8 2004 2 06 93-100 |
| spelling |
10.1007/BF03260051 doi (DE-627)SPR035370548 (SPR)BF03260051-e DE-627 ger DE-627 rakwb eng Scaruffi, Paola verfasserin aut Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2004 Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. Neuroblastoma (dpeaa)DE-He213 Comparative Genomic Hybridization (dpeaa)DE-He213 MYCN Amplification (dpeaa)DE-He213 Neuroblastoma Patient (dpeaa)DE-He213 MYCN Gene (dpeaa)DE-He213 Parodi, Stefano aut Mazzocco, Katia aut Defferrari, Raffaella aut Fontana, Vincenzo aut Bonassi, Stefano aut Tonini, Gian Paolo aut Enthalten in Molecular diagnosis & therapy [S.l.] : Springer International, 2006 8(2004), 2 vom: Juni, Seite 93-100 (DE-627)51122799X (DE-600)2232973-0 1179-2000 nnns volume:8 year:2004 number:2 month:06 pages:93-100 https://dx.doi.org/10.1007/BF03260051 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 AR 8 2004 2 06 93-100 |
| allfields_unstemmed |
10.1007/BF03260051 doi (DE-627)SPR035370548 (SPR)BF03260051-e DE-627 ger DE-627 rakwb eng Scaruffi, Paola verfasserin aut Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2004 Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. Neuroblastoma (dpeaa)DE-He213 Comparative Genomic Hybridization (dpeaa)DE-He213 MYCN Amplification (dpeaa)DE-He213 Neuroblastoma Patient (dpeaa)DE-He213 MYCN Gene (dpeaa)DE-He213 Parodi, Stefano aut Mazzocco, Katia aut Defferrari, Raffaella aut Fontana, Vincenzo aut Bonassi, Stefano aut Tonini, Gian Paolo aut Enthalten in Molecular diagnosis & therapy [S.l.] : Springer International, 2006 8(2004), 2 vom: Juni, Seite 93-100 (DE-627)51122799X (DE-600)2232973-0 1179-2000 nnns volume:8 year:2004 number:2 month:06 pages:93-100 https://dx.doi.org/10.1007/BF03260051 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 AR 8 2004 2 06 93-100 |
| allfieldsGer |
10.1007/BF03260051 doi (DE-627)SPR035370548 (SPR)BF03260051-e DE-627 ger DE-627 rakwb eng Scaruffi, Paola verfasserin aut Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2004 Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. Neuroblastoma (dpeaa)DE-He213 Comparative Genomic Hybridization (dpeaa)DE-He213 MYCN Amplification (dpeaa)DE-He213 Neuroblastoma Patient (dpeaa)DE-He213 MYCN Gene (dpeaa)DE-He213 Parodi, Stefano aut Mazzocco, Katia aut Defferrari, Raffaella aut Fontana, Vincenzo aut Bonassi, Stefano aut Tonini, Gian Paolo aut Enthalten in Molecular diagnosis & therapy [S.l.] : Springer International, 2006 8(2004), 2 vom: Juni, Seite 93-100 (DE-627)51122799X (DE-600)2232973-0 1179-2000 nnns volume:8 year:2004 number:2 month:06 pages:93-100 https://dx.doi.org/10.1007/BF03260051 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 AR 8 2004 2 06 93-100 |
| allfieldsSound |
10.1007/BF03260051 doi (DE-627)SPR035370548 (SPR)BF03260051-e DE-627 ger DE-627 rakwb eng Scaruffi, Paola verfasserin aut Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2004 Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. Neuroblastoma (dpeaa)DE-He213 Comparative Genomic Hybridization (dpeaa)DE-He213 MYCN Amplification (dpeaa)DE-He213 Neuroblastoma Patient (dpeaa)DE-He213 MYCN Gene (dpeaa)DE-He213 Parodi, Stefano aut Mazzocco, Katia aut Defferrari, Raffaella aut Fontana, Vincenzo aut Bonassi, Stefano aut Tonini, Gian Paolo aut Enthalten in Molecular diagnosis & therapy [S.l.] : Springer International, 2006 8(2004), 2 vom: Juni, Seite 93-100 (DE-627)51122799X (DE-600)2232973-0 1179-2000 nnns volume:8 year:2004 number:2 month:06 pages:93-100 https://dx.doi.org/10.1007/BF03260051 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 AR 8 2004 2 06 93-100 |
| language |
English |
| source |
Enthalten in Molecular diagnosis & therapy 8(2004), 2 vom: Juni, Seite 93-100 volume:8 year:2004 number:2 month:06 pages:93-100 |
| sourceStr |
Enthalten in Molecular diagnosis & therapy 8(2004), 2 vom: Juni, Seite 93-100 volume:8 year:2004 number:2 month:06 pages:93-100 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Neuroblastoma Comparative Genomic Hybridization MYCN Amplification Neuroblastoma Patient MYCN Gene |
| isfreeaccess_bool |
false |
| container_title |
Molecular diagnosis & therapy |
| authorswithroles_txt_mv |
Scaruffi, Paola @@aut@@ Parodi, Stefano @@aut@@ Mazzocco, Katia @@aut@@ Defferrari, Raffaella @@aut@@ Fontana, Vincenzo @@aut@@ Bonassi, Stefano @@aut@@ Tonini, Gian Paolo @@aut@@ |
| publishDateDaySort_date |
2004-06-01T00:00:00Z |
| hierarchy_top_id |
51122799X |
| id |
SPR035370548 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035370548</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519114446.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2004 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03260051</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035370548</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03260051-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Scaruffi, Paola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis Data Information BV 2004</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroblastoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Comparative Genomic Hybridization</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MYCN Amplification</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroblastoma Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MYCN Gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parodi, Stefano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazzocco, Katia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Defferrari, Raffaella</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fontana, Vincenzo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonassi, Stefano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tonini, Gian Paolo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Molecular diagnosis & therapy</subfield><subfield code="d">[S.l.] : Springer International, 2006</subfield><subfield code="g">8(2004), 2 vom: Juni, Seite 93-100</subfield><subfield code="w">(DE-627)51122799X</subfield><subfield code="w">(DE-600)2232973-0</subfield><subfield code="x">1179-2000</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:93-100</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03260051</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2004</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">93-100</subfield></datafield></record></collection>
|
| author |
Scaruffi, Paola |
| spellingShingle |
Scaruffi, Paola misc Neuroblastoma misc Comparative Genomic Hybridization misc MYCN Amplification misc Neuroblastoma Patient misc MYCN Gene Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization |
| authorStr |
Scaruffi, Paola |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)51122799X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-2000 |
| topic_title |
Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization Neuroblastoma (dpeaa)DE-He213 Comparative Genomic Hybridization (dpeaa)DE-He213 MYCN Amplification (dpeaa)DE-He213 Neuroblastoma Patient (dpeaa)DE-He213 MYCN Gene (dpeaa)DE-He213 |
| topic |
misc Neuroblastoma misc Comparative Genomic Hybridization misc MYCN Amplification misc Neuroblastoma Patient misc MYCN Gene |
| topic_unstemmed |
misc Neuroblastoma misc Comparative Genomic Hybridization misc MYCN Amplification misc Neuroblastoma Patient misc MYCN Gene |
| topic_browse |
misc Neuroblastoma misc Comparative Genomic Hybridization misc MYCN Amplification misc Neuroblastoma Patient misc MYCN Gene |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Molecular diagnosis & therapy |
| hierarchy_parent_id |
51122799X |
| hierarchy_top_title |
Molecular diagnosis & therapy |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)51122799X (DE-600)2232973-0 |
| title |
Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization |
| ctrlnum |
(DE-627)SPR035370548 (SPR)BF03260051-e |
| title_full |
Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization |
| author_sort |
Scaruffi, Paola |
| journal |
Molecular diagnosis & therapy |
| journalStr |
Molecular diagnosis & therapy |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2004 |
| contenttype_str_mv |
txt |
| container_start_page |
93 |
| author_browse |
Scaruffi, Paola Parodi, Stefano Mazzocco, Katia Defferrari, Raffaella Fontana, Vincenzo Bonassi, Stefano Tonini, Gian Paolo |
| container_volume |
8 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Scaruffi, Paola |
| doi_str_mv |
10.1007/BF03260051 |
| title_sort |
detection of mycn amplification and chromosome 1p36 loss in neuroblastoma by cdna microarray comparative genomic hybridization |
| title_auth |
Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization |
| abstract |
Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. © Adis Data Information BV 2004 |
| abstractGer |
Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. © Adis Data Information BV 2004 |
| abstract_unstemmed |
Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions. © Adis Data Information BV 2004 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 |
| container_issue |
2 |
| title_short |
Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization |
| url |
https://dx.doi.org/10.1007/BF03260051 |
| remote_bool |
true |
| author2 |
Parodi, Stefano Mazzocco, Katia Defferrari, Raffaella Fontana, Vincenzo Bonassi, Stefano Tonini, Gian Paolo |
| author2Str |
Parodi, Stefano Mazzocco, Katia Defferrari, Raffaella Fontana, Vincenzo Bonassi, Stefano Tonini, Gian Paolo |
| ppnlink |
51122799X |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03260051 |
| up_date |
2024-07-03T14:17:31.626Z |
| _version_ |
1803567761085956097 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035370548</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519114446.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2004 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03260051</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035370548</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03260051-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Scaruffi, Paola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis Data Information BV 2004</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma. Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer. Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH. Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification. Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroblastoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Comparative Genomic Hybridization</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MYCN Amplification</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroblastoma Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MYCN Gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parodi, Stefano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazzocco, Katia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Defferrari, Raffaella</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fontana, Vincenzo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonassi, Stefano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tonini, Gian Paolo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Molecular diagnosis & therapy</subfield><subfield code="d">[S.l.] : Springer International, 2006</subfield><subfield code="g">8(2004), 2 vom: Juni, Seite 93-100</subfield><subfield code="w">(DE-627)51122799X</subfield><subfield code="w">(DE-600)2232973-0</subfield><subfield code="x">1179-2000</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:93-100</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03260051</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2004</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">93-100</subfield></datafield></record></collection>
|
| score |
7.4006567 |